吸入用布地奈德混悬液与布地奈德粉吸入剂治疗急性加重期慢性阻塞性肺疾病的临床效果比较

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF (0 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨吸入用布地奈德混悬液与布地奈德粉吸入剂治疗急性加重期慢性阻塞性肺疾病（COPD）的临床效果差异，以期为急性加重期COPD 临床治疗提供参考。方法选取2018年1～12月在江西省人民医院呼吸科入院的120 例急性加重期COPD 患者作为研究对象，采用随机数字表法将其分为两组，每组各60 例。两组均给予基础治疗，在此基础上，普米克令舒组患者采用吸入用布地奈德混悬液治疗，普米克都保组患者采用布地奈德粉吸入剂治疗。比较两组患者入院第1 天和第7 天的血气分析指标[血氧饱和度（SpO2）、二氧化碳分压（PCO2）、pH值、HCO3-]，比较两组患者出院3 个月内的重复住院率。结果入院第1、7 天，两组患者的SpO2、PCO2、pH 值、HCO3-含量比较，差异均无统计学意义（P＞0.05）。入院第7 天，两组患者的SpO2、pH 值、HCO3-含量均高于本组入院第1 天，差异有统计学意义（P＜0.05）。入院第7 天，两组患者的PCO2 均低于本组入院第1 天，差异有统计学意义（P＜0.05）。两组患者出院后3 个月内的重复住院率比较，差异无统计学意义（P＞0.05）。结论吸入用布地奈德混悬液和布地奈德粉吸入剂治疗急性加重期COPD 均具有较好的治疗效果，值得临床应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	肖立奇
	李晓芸
	刘芸
	董永海

关键词 ：吸入用布地奈德混悬液, 布地奈德粉吸入剂, 慢性阻塞性肺疾病, 临床效果

Abstract：Objective To explore the clinical effect difference of Budesonide Suspension for Inhalation and Budesonide Powder for Inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD), and to provide reference for clinical treatment of acute exacerbation of COPD.Methods A total of 120 patients with acute exacerbation of COPD admitted to the Department of Respiration of Jiangxi Provincial People′s Hospital from January to December 2018 were selected as subjects in the study.Both groups were given basic treatment.On this basis, patients in the Pulmicort Respulas group were treated with Budesonide Suspension for Inhalation, while patients in the Pulmicort Turbuhaler group were treated with Budesonide Powder for Inhalation.Blood gas analysis indexes (blood oxygen saturation [SpO2], partial pressure of carbon dioxide [PCO2], pH value, HCO3-) of the two groups were compared on the 1st and 7th day of admission, and the repeated hospitalization rates of the two groups within 3 months of discharge were compared.Results On the 1st and 7th day of admission, SpO2, PCO2, pH value and HCO3- of the patients in the two groups were compared, and the differences were not statistically significant (P＞0.05).On the 7th day of admission, SpO2,pH value and HCO3- of patients in the two groups were higher than those on the 1st day of admission, with statistically significant differences (P＜0.05).On the 7th day of admission, PCO2 of both groups were lower than those of this group on the 1st day of admission, with statistically significant differences (P＜0.05).There was no significant difference between the two groups in the repeated hospitalization rate within 3 months after discharge (P＞0.05).Conclusion Budesonide Suspension for Inhalation and Budesonide Powder for Inhalation have good therapeutic effect on acute exacerbation COPD and are worthy of clinical application.

Key words： Budesonide Suspension for Inhalation;Budesonide Powder for Inhalation Chronic obstructive pulmonary disease Clinical effect

基金资助:江西省卫生计生委科技计划项目（20195027）

作者简介: 肖立奇（1985-），女，江西南昌人，本科，护师，研究方向：呼吸系统疾病

引用本文:

肖立奇; 李晓芸; 刘芸; 董永海. 吸入用布地奈德混悬液与布地奈德粉吸入剂治疗急性加重期慢性阻塞性肺疾病的临床效果比较[J]. 中国当代医药, 2020, 27(3): 35-38.
XIAO Li-qi; LI Xiao-yun; LIU Yun; DONG Yong-hai. Clinical effect comparison of Budesonide Suspension for Inhalation and Budesonide Powder for Inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease. 中国当代医药, 2020, 27(3): 35-38.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I3/35

[1]	Boehm A，Pizzini A，Sonnweber T，et al.Assessing global COPD awareness with Google Trends[J].Eur Respir J，2019，53（6）：1-24.
[2]	Ding H，Karunanithi M，Ireland D，et al.Evaluation of an innovative mobile health programme for the self-management of chronic obstructive pulmonary disease（MH-COPD）：protocol of a randomised controlled trial[J].BMJ Open，2019，9（4）：e25381.
[3]	Jenkins BA，Athilingam P，Jenkins RA.Symptom clusters in chronic obstructive pulmonary disease：A systematic review[J].Appl Nurs Res，2019，45：23-29.
[4]	Sidhaye VK，Nishida K，Martinez FJ.Precision medicine in COPD：where are we and where do we need to go？[J].Eur Respir Rev，2018，27（149）：1-23.
[5]	Claudett KH，Grunauer M.Role of domiciliary noninvasive ventilation in chronic obstructive pulmonary disease patients requiring repeated admissions with acute type Ⅱrespiratory failure：a prospective cohort study[J].Indian J Crit Care Med，2019，23（1）：56-57.
[6]	Trethewey SP，Edgar RG，Morlet J，et al.Late presentation of acute hypercapnic respiratory failure carries a high mortality risk in COPD patients treated with ward-based NIV[J].Respir Med，2019，151：128-132.
[7]	何添标，黎艳聪，李明标，等.吸入用布地奈德混悬液联合吸入用复方异丙托溴铵溶液治疗慢性阻塞性肺疾病急性加重期的疗效观察[J].中国医院用药评价与分析，2019，19（2）：147-149，152.
[8]	赵建，严婷，倪英.糖皮质激素不同给药方式治疗慢性阻塞性肺疾病急性加重期的疗效观察[J].中国医院用药评价与分析，2019，19（2）：161-163.
[9]	陈亚红.2018年GOLD 慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J].中国医学前沿杂志（电子版），2017，9（12）：15-22.
[10]	包鹤龄，方利文，王临虹.1990～2014年中国40 岁及以上人群慢性阻塞性肺疾病患病率Meta 分析[J].中华流行病学杂志，2016，37（1）：119-124.
[11]	Zhu B，Wang Y，Ming J，et al.Disease burden of COPD in China：a systematic review[J].Int J Chron Obstruct Pulmon Dis，2018，13：1353-1364.
[12]	Quaderi SA，Hurst JR.The unmet global burden of COPD[J].Glob Health Epidemiol Genomics，2018，3：e4.
[13]	Igarashi A，Fukuchi Y，Hirata K，et al.COPD uncovered：a cross-sectional study to assess the socioeconomic burden of COPD in Japan[J].Int J Chronic Obstructive Pulmonnary Dis，2018，13：2629-2641.
[14]	陈义荣，陆小辉.甲强龙与普米克令舒在老年慢性阻塞性肺疾病急性加重期疗效分析[J].北方药学，2018，15（11）：18-19.
[15]	王赶云.用普米克令舒对老年慢性阻塞性肺疾病患者进行治疗的效果研究[J].当代医药论丛，2018，16（19）：120-122.
[16]	李章.联用可必特与普米克都保对小儿支气管哮喘急性发作患儿进行氧气驱动雾化吸入治疗的效果[J].当代医药论丛，2017，15（23）：164-165.
[17]	刘海燕，侯伟，李静，等.普米克都保联合沙丁胺醇对咳嗽变异性哮喘患儿的疗效分析[J].现代生物医学进展，2017，17（6）：1073-1075，1123.
[18]	Emami AM，Klantar E，Azimian M.Comparison of the efficacy of Budesonide Nebulizer Suspension and Budesonide Inhalation Suspension in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].Tanaffos，2018，17（2）：96-102.